Daehan Nupharm KRX:054670KOSDAQ
대한뉴팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Daehan Nupharm reported revenue of ₩56.0bn, up 12.2% year on year, and operating profit of ₩2.2bn. Daehan Nupharm (대한뉴팜) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 1 article.
Filing signals Share pledge Screener
Daehan Nupharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩56.0bn | +12.2% | ₩2.2bn margin 3.8% | ₩11.3bn |
| Q1 2026 | ₩54.8bn | +5.8% | ₩3.1bn margin 5.7% | ₩3.0bn |
| Q4 2025 derived | ₩51.8bn | +1.6% | ₩2.3bn margin 4.5% | ₩7.1bn |
| Q3 2025 | ₩48.9bn | +0.2% | ₩2.1bn margin 4.3% | ₩2.6bn |
| Q2 2025 | ₩49.9bn | -7.9% | ₩3.1bn margin 6.1% | ₩3.0bn |
| Q1 2025 | ₩51.9bn | +7.4% | ₩4.2bn margin 8.2% | ₩2.6bn |
| Q4 2024 derived | ₩51.0bn | +0.7% | ₩3.8bn margin 7.4% | ₩2.7bn |
| Q3 2024 | ₩48.8bn | -0.8% | ₩4.1bn margin 8.3% | ₩2.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Daehan Nupharm top stories 2 weeks, by number of outlets
- 1